Pellets for oral administration of low-molecular-weight heparin

Drug Development and Industrial Pharmacy

Volumn 35, Issue 12, 2009, Pages 1503-1510

  Scala Bertola, Julien ^a   Gajdziok, Jan ^b   Rabišková, Miloslava ^b   Bonneaux, Franois ^a   Lecompte, Thomas ^a   Sapin, Anne ^a   Maincent, Philippe ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

^b UNIVERSITY OF VETERINARY AND PHARMACEUTICAL SCIENCES   (Czech Republic)

Author keywords

Anti Xa activity in vivo; Drug release in vitro; Eudragit RS30D; Low molecular weight heparin; Oral heparin delivery; Pellets

Indexed keywords

ACETYLTRIETHYL CITRATE; BEMIPARIN; CITRIC ACID TRIETHYL ESTER; ENOXAPARIN; EUDRAGIT; LACTOSE; METHOCEL E5; METHYLCELLULOSE; MICROCRYSTALLINE CELLULOSE; PHOSPHATE BUFFERED SALINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG PELLET; DRUG RELEASE; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; RABBIT; SINGLE DRUG DOSE; SPHERONIZATION;

ACRYLIC RESINS; ADMINISTRATION, ORAL; ANIMALS; ANTICOAGULANTS; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; ENOXAPARIN; FACTOR XA; HEPARIN, LOW-MOLECULAR-WEIGHT; MALE; MECHANICAL PHENOMENA; PARTICLE SIZE; PHARMACEUTIC AIDS; RABBITS; SOLUBILITY; TIME FACTORS;

EID: 71049133992     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639040903037207     Document Type: Article

References (33)

1. Lane DA, MacGregor IR, VanRoss M, Cella G, Kakkar VV. (1979). Molecular weight dependence of the anticoagulant properties of heparin: Intravenous and subcutaneous administration of fractionated heparins to man. Thromb Res, 16:651-662
2. Weitz JI. (1997). Low-molecular-weight heparins. N Engl J Med, 337:688-698
3. Kakkar AK. (2004). Low- and ultra-low-molecular-weight heparins. Best Pract Res Clin Haematol, 17:77-87.
4. Money SR, York JW. (2001). Development of oral heparin therapy for prophylaxis and treatment of deep venous thrombosis. Cardiovasc Surg, 9:211-218
5. Motlekar NA, Youan BB. (2006). The quest for non-invasive delivery of bioactive macromolecules: A focus on heparins. J Control Release, 113:91-101.
6. Thanou M, Verhoef JC, Nihot MT, Verheijden JH, Junginger HE. (2001). Enhancement of the intestinal absorption of low molecular weight heparin (LMWH) in rats and pigs using Carbopol 934P. Pharm Res, 18:1638-1641
7. Bernkop-Schnurch A, Kast CE, Guggi D. (2003). Permeation enhancing polymers in oral delivery of hydrophilic macromolecules: Thiomer/GSH systems. J Control Release, 93:95-103.
8. Schmitz T, Leitner VM, Bernkop-Schnurch A. (2005). Oral heparin delivery: Design and in vivo evaluation of a stomachtargeted mucoadhesive delivery system. J Pharm Sci, 94:966-973
9. Motlekar NA, Srivenugopal KS, Wachtel MS, Youan BB. (2006). Evaluation of the oral bioavailability of low molecular weight heparin formulated with glycyrrhetinic acid as permeation enhancer. Drug Dev Res, 67:166-174
10. Motlekar NA, Srivenugopal KS, Wachtel MS, Youan BB. (2006). Modulation of gastrointestinal permeability of low-molecularweight heparin by L-arginine: In-vivo and in-vitro evaluation. J Pharm Pharmacol, 58:591-598
11. Motlekar NA, Srivenugopal KS, Wachtel MS, Youan BB. (2005). Oral delivery of low-molecular-weight heparin using sodium caprate as absorption enhancer reaches therapeutic levels. J Drug Target, 13:573-583
12. Thanou M, Henderson S, Kydonieus A, Elson C. (2007). N-sulfonato- N, O-carboxymethylchitosan: A novel polymeric absorption enhancer for the oral delivery of macromolecules. J Control Release, 117:171-178
13. Rama Prasad YV, Minamimoto T, Yoshikawa Y, Shibata N, Mori S, Matsuura A, et al. (2004). In situ intestinal absorption studies on low molecular weight heparin in rats using labrasol as absorption enhancer. Int J Pharm, 271:225-232
14. Kim SK, Lee DY, Lee E, Lee YK, Kim CY, Moon HT, et al. (2007). Absorption study of deoxycholic acid-heparin conjugate as a new form of oral anti-coagulant. J Control Release, 120:4-10.
15. Berkowitz SD, Marder VJ, Kosutic G, Baughman RA. (2003). Oral heparin administration with a novel drug delivery agent (SNAC) in healthy volunteers and patients undergoing elective total hip arthroplasty. J Thromb Haemost, 1:1914-1919
16. Lever R, Page CP. (2002). Novel drug development opportunities for heparin. Nat Rev Drug Discov, 1:140-148
17. Hoffart V, Lamprecht A, Maincent P, Lecompte T, Vigneron C, Ubrich N. (2006). Oral bioavailability of a low molecular weight heparin using a polymeric delivery system. J Control Release, 113:38-42.
18. Jiao Y, Ubrich N, Hoffart V, Marchand-Arvier M, Vigneron C, Hoffman M, et al. (2002). Anticoagulant activity of heparin following oral administration of heparin-loaded microparticles in rabbits. J Pharm Sci, 91:760-768
19. Jiao Y, Ubrich N, Marchand-Arvier M, Vigneron C, Hoffman M, Lecompte T, et al. (2002). In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits. Circulation, 105:230-235
20. Lamprecht A, Ubrich N, Maincent P. (2007). Oral low molecular weight heparin delivery by microparticles from complex coacervation. Eur J Pharm Biopharm, 67:632-638
21. Gerotziafas GT, Petropoulou AD, Verdy E, Samama MM, Elalamy I. (2007). Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation. J Thromb Haemost, 5:955-962
22. Rabiŝková M, Pérez JP. (2002). The role of the moistering agent in the process of extrusion and spheronization. Ces Slov Farm, 51:244-247
23. Haring A, Vetchy D, Janovska L, Krejcova K, Rabiskova M. (2008). Differences in characteristics of pellets prepared by different pelletization methods. Drug Dev Ind Pharm, 34:289-296
24. Hoffart V, Ubrich N, Lamprecht A, Bachelier K, Vigneron C, Lecompte T, et al. (2003). Microencapsulation of low molecular weight heparin into polymeric particles designed with biodegradable and nonbiodegradable polycationic polymers. Drug Deliv, 10:1-7.
25. Teien AN, Lie M. (1977). Evaluation of an amidolytic heparin assay method: Increased sensitivity by adding purified antithrombin III. Thromb Res, 10:399-410.
26. Vertommen J, Kinget R. (1997). The influence of five selected processing and formulation variables on the particle size, particle size distribution, and friability of pellets produced in a rotary processor. Drug Dev Ind Pharm, 23:39-46.
27. Rodriguez EC, Torrado JJ, Nikolakakis I, Torrado S, Lastres JL, Malamataris S. (2001). Micromeritic and packing properties of diclofenac pellets and effects of some formulation variables. Drug Dev Ind Pharm, 27:847-855
28. Bianchini P, Bergonzini GL, Parma B, Osima B. (1995). Relationship between plasma antifactor Xa activity and the antithrombotic activity of heparins of different molecular mass. Haemostasis, 25:288-298
29. Lamprecht A, Koenig P, Ubrich N, Maincent P, Neumann D. (2006). Low molecular weight heparin nanoparticles: Mucoadhesion and behaviour in Caco-2 cells. Nanotechnology, 17:3673-3680
30. Jandik KA, Kruep D, Cartier M, Linhardt RJ. (1996). Accelerated stability studies of heparin. J Pharm Sci, 85:45-51.
31. Ahn MY, Shin KH, Kim DH, Jung EA, Toida T, Linhardt RJ, et al. (1998). Characterization of a bacteroides species from human intestine that degrades glycosaminoglycans. Can J Microbiol, 44:423-429
32. Thanou M, Nihot MT, Jansen M, Verhoef JC, Junginger HE. (2001). Mono-N-carboxymethyl chitosan (MCC), a polyampholytic chitosan derivative, enhances the intestinal absorption of low molecular weight heparin across intestinal epithelia in vitro and in vivo. J Pharm Sci, 90:38-46.
33. Thanou M, Verhoef JC, Junginger HE. (2001). Oral drug absorption enhancement by chitosan and its derivatives. Adv Drug Deliv Rev, 52:117-126 (Pubitemid 33079167)